ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
暂无分享,去创建一个
Kedar S Vaidya | A. Phillips | Dong Cheng | M. Mitten | N. Goodwin | E. Boghaert | J. Meulbroek | E. Reilly | F. G. Buchanan | P. Devries | Laura M. Mckay | H. D. Falls | Suzanne Norvell
[1] S. Singer,et al. Final results from the dose-escalation stage of a phase 1/2 trial of TPI 287, a brain penetrable microtubule inhibitor, plus bevacizumab in patients with recurrent glioblastoma. , 2017 .
[2] A. Tolcher,et al. ABT-414 in patients with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR). , 2015 .
[3] T. Arora,et al. AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma , 2015, Molecular Cancer Therapeutics.
[4] G. Shapiro,et al. A phase 1 study of ABT-806 in subjects with advanced solid tumors , 2015, Investigational New Drugs.
[5] Bonnie L Boster,et al. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer , 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[6] H. Xiong,et al. Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR , 2015, Clinical Pharmacokinetics.
[7] A. Scott,et al. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody , 2015, Molecular Cancer Therapeutics.
[8] Steven J. M. Jones,et al. Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.
[9] L. Landi,et al. Pharmacotherapy targeting the EGFR oncogene in NSCLC , 2014, Expert opinion on pharmacotherapy.
[10] Mauricio Leal,et al. Antibody–drug conjugates: an emerging modality for the treatment of cancer , 2014, Annals of the New York Academy of Sciences.
[11] M. J. van den Bent,et al. A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM). , 2014 .
[12] P. Senter,et al. Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drug. , 2014, Hematology/oncology clinics of North America.
[13] P. Jänne,et al. The quest to overcome resistance to EGFR-targeted therapies in cancer , 2013, Nature Medicine.
[14] Steven J. M. Jones,et al. Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.
[15] A. Scott,et al. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. , 2012, Cancer research.
[16] D. Tindall,et al. Abstract 2924: Constitutively active androgen receptor splice variants function independently of full-length androgen receptor in a cell-based model of castrate-resistant prostate cancer , 2012 .
[17] Jason S. Lewis,et al. Magnitude of Enhanced Permeability and Retention Effect in Tumors with Different Phenotypes: 89Zr-Albumin as a Model System , 2011, Journal of Nuclear Medicine.
[18] Jun Fang,et al. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. , 2011, Advanced drug delivery reviews.
[19] L. Roskos,et al. Pharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab , 2010, Clinical pharmacokinetics.
[20] M. Meyerson,et al. Amplification of chromosomal segment 4q12 in non-small cell lung cancer , 2009, Cancer biology & therapy.
[21] R. Perez-soler,et al. Skin toxicities associated with epidermal growth factor receptor inhibitors , 2009, Targeted Oncology.
[22] Webster K. Cavenee,et al. Antibodies specifically targeting a locally misfolded region of tumor associated EGFR , 2009, Proceedings of the National Academy of Sciences.
[23] P. Senter,et al. Novel peptide linkers for highly potent antibody-auristatin conjugate. , 2008, Bioconjugate chemistry.
[24] Antony W Burgess,et al. EGFR family: Structure physiology signalling and therapeutic targets† , 2008, Growth factors.
[25] A. Scott,et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors , 2007, Proceedings of the National Academy of Sciences.
[26] H. Sasaki,et al. EGFRvIII mutation in lung cancer correlates with increased EGFR copy number. , 2007, Oncology reports.
[27] Jennifer L Hunt,et al. Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting , 2006, Clinical Cancer Research.
[28] John Mendelsohn,et al. Epidermal growth factor receptor targeting in cancer. , 2006, Seminars in oncology.
[29] C. Discafani,et al. Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy. , 2006, International journal of oncology.
[30] J. Henson,et al. Treatment of glioblastoma multiforme: a new standard. , 2006, Archives of neurology.
[31] D. Blumenthal,et al. Survival outcomes in glioblastoma multiforme, including the impact of adjuvant chemotherapy , 2005, Expert review of neurotherapeutics.
[32] H. Modjtahedi,et al. Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. , 2005, International journal of oncology.
[33] Michael Peyton,et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. , 2005, Cancer research.
[34] F. Khuri,et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[35] L. Norton,et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] R. McLendon,et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. , 1995, Cancer research.
[37] Y H Xu,et al. Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells , 1985, Molecular and cellular biology.
[38] B. Brown,et al. Modulation of cyclic AMP accumulation in GH3 cells by a phorbol ester and thyroliberin. , 1985, Biochemical and biophysical research communications.
[39] M N Pollak,et al. MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. , 1985, Biochemical and biophysical research communications.
[40] I. Pastan,et al. Elevated epidermal growth factor receptor gene copy number and expression in a squamous carcinoma cell line. , 1985, The Journal of clinical investigation.
[41] Christopher D. Brown,et al. Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma. , 2015, Oral oncology.
[42] A. Enrique,et al. Role of anti-EGFR target therapy in colorectal carcinoma. , 2012, Frontiers in bioscience.
[43] Damon L. Meyer,et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. , 2006, Bioconjugate chemistry.